Incyte Corporation Stock

Equities

INCY

US45337C1027

Pharmaceuticals

Delayed Nasdaq 15:51:56 2024-07-16 EDT 5-day change 1st Jan Change
64.08 USD -0.26% Intraday chart for Incyte Corporation +5.42% +1.91%
Sales 2024 * 4.08B 5.58B Sales 2025 * 4.5B 6.15B Capitalization 14.45B 19.75B
Net income 2024 * 815M 1.11B Net income 2025 * 950M 1.3B EV / Sales 2024 * 2.7 x
Net cash position 2024 * 3.43B 4.69B Net cash position 2025 * 4.94B 6.76B EV / Sales 2025 * 2.11 x
P/E ratio 2024 *
18.1 x
P/E ratio 2025 *
15.5 x
Employees 2,524
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.28%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.40%
1 week+5.42%
Current month+5.56%
1 month+2.07%
3 months+20.24%
6 months+4.32%
Current year+1.91%
More quotes
1 week
59.74
Extreme 59.74
64.59
1 month
56.75
Extreme 56.75
64.59
Current year
50.35
Extreme 50.3498
67.37
1 year
50.27
Extreme 50.27
67.37
3 years
50.27
Extreme 50.27
86.29
5 years
50.27
Extreme 50.27
110.37
10 years
43.86
Extreme 43.86
153.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 14-01-12
Director of Finance/CFO 53 19-02-10
Chief Tech/Sci/R&D Officer 57 15-03-01
Members of the board TitleAgeSince
Director/Board Member 57 00-12-31
Director/Board Member 71 19-12-15
Director/Board Member 70 15-01-19
More insiders
Date Price Change Volume
24-07-16 64.08 -0.26% 863 893
24-07-15 64.25 +0.93% 1,577,594
24-07-12 63.66 +2.20% 1,934,890
24-07-11 62.29 +2.57% 2,268,682
24-07-10 60.73 +0.05% 2,525,127

Delayed Quote Nasdaq, July 16, 2024 at 03:51 pm

More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
64.25 USD
Average target price
72.66 USD
Spread / Average Target
+13.10%
Consensus